Cargando…

mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines

The advent of the Omicron variant globally has hastened the requirement for a booster vaccination dose to confer continuous protection against symptomatic SARS-CoV2 infection. However, different vaccines are available in different countries, and individuals who had adverse reactions to certain vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Biyan, Huo, Jianxin, Huang, Yuhan, Teo, Shuan Yong, Duan, Kaibo, Li, Yanfeng, Toh, Lim Kai, Lam, Kong Peng, Xu, Shengli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315817/
https://www.ncbi.nlm.nih.gov/pubmed/35891221
http://dx.doi.org/10.3390/vaccines10071057
_version_ 1784754656087375872
author Zhang, Biyan
Huo, Jianxin
Huang, Yuhan
Teo, Shuan Yong
Duan, Kaibo
Li, Yanfeng
Toh, Lim Kai
Lam, Kong Peng
Xu, Shengli
author_facet Zhang, Biyan
Huo, Jianxin
Huang, Yuhan
Teo, Shuan Yong
Duan, Kaibo
Li, Yanfeng
Toh, Lim Kai
Lam, Kong Peng
Xu, Shengli
author_sort Zhang, Biyan
collection PubMed
description The advent of the Omicron variant globally has hastened the requirement for a booster vaccination dose to confer continuous protection against symptomatic SARS-CoV2 infection. However, different vaccines are available in different countries, and individuals who had adverse reactions to certain vaccine types require heterologous vaccine boosters. To understand the efficacy of different vaccination regimens in inducing humoral responses to SARS-CoV2, we examined plasma antibodies and frequencies of Omicron RBD-specific B cells in individuals who had different priming-booster vaccination regimens. We found that individuals with three homologous doses of mRNA vaccines had higher levels of IgG of all subclasses against RBD of Omicron than individuals with three homologous doses of inactivated virus vaccine. A booster with mRNA vaccine resulted in significant increases in median levels of RBD-reactive IgG1 (17–19 fold) and IgG3 (2.3–3.3 fold) as compared to individuals receiving inactivated virus booster shots regardless of priming vaccine types. More importantly, individuals who received a booster dose of mRNA vaccine, irrespective of the priming vaccine, had antibodies with higher neutralizing capability against the Omicron variant than those who received a booster dose of inactivated virus vaccine. Corroborating the antibody results, boosting with the mRNA vaccine increased the frequencies of Omicron RBD-binding B cells by (1.5–3.3 fold) regardless of priming vaccine types. Together, our data demonstrate that an mRNA vaccine (BNT162b2 or mRNA-1273) booster enhances humoral responses against the Omicron variant in individuals vaccinated with either two prior doses of mRNA or inactivated virus vaccine (CoronaVac or BBIBP-CorV), potentially providing more effective protection against SARS-CoV-2 infection, particularly by the Omicron variant.
format Online
Article
Text
id pubmed-9315817
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93158172022-07-27 mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines Zhang, Biyan Huo, Jianxin Huang, Yuhan Teo, Shuan Yong Duan, Kaibo Li, Yanfeng Toh, Lim Kai Lam, Kong Peng Xu, Shengli Vaccines (Basel) Article The advent of the Omicron variant globally has hastened the requirement for a booster vaccination dose to confer continuous protection against symptomatic SARS-CoV2 infection. However, different vaccines are available in different countries, and individuals who had adverse reactions to certain vaccine types require heterologous vaccine boosters. To understand the efficacy of different vaccination regimens in inducing humoral responses to SARS-CoV2, we examined plasma antibodies and frequencies of Omicron RBD-specific B cells in individuals who had different priming-booster vaccination regimens. We found that individuals with three homologous doses of mRNA vaccines had higher levels of IgG of all subclasses against RBD of Omicron than individuals with three homologous doses of inactivated virus vaccine. A booster with mRNA vaccine resulted in significant increases in median levels of RBD-reactive IgG1 (17–19 fold) and IgG3 (2.3–3.3 fold) as compared to individuals receiving inactivated virus booster shots regardless of priming vaccine types. More importantly, individuals who received a booster dose of mRNA vaccine, irrespective of the priming vaccine, had antibodies with higher neutralizing capability against the Omicron variant than those who received a booster dose of inactivated virus vaccine. Corroborating the antibody results, boosting with the mRNA vaccine increased the frequencies of Omicron RBD-binding B cells by (1.5–3.3 fold) regardless of priming vaccine types. Together, our data demonstrate that an mRNA vaccine (BNT162b2 or mRNA-1273) booster enhances humoral responses against the Omicron variant in individuals vaccinated with either two prior doses of mRNA or inactivated virus vaccine (CoronaVac or BBIBP-CorV), potentially providing more effective protection against SARS-CoV-2 infection, particularly by the Omicron variant. MDPI 2022-06-30 /pmc/articles/PMC9315817/ /pubmed/35891221 http://dx.doi.org/10.3390/vaccines10071057 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhang, Biyan
Huo, Jianxin
Huang, Yuhan
Teo, Shuan Yong
Duan, Kaibo
Li, Yanfeng
Toh, Lim Kai
Lam, Kong Peng
Xu, Shengli
mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
title mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
title_full mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
title_fullStr mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
title_full_unstemmed mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
title_short mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
title_sort mrna booster vaccination enhances antibody responses against sars-cov2 omicron variant in individuals primed with mrna or inactivated virus vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315817/
https://www.ncbi.nlm.nih.gov/pubmed/35891221
http://dx.doi.org/10.3390/vaccines10071057
work_keys_str_mv AT zhangbiyan mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines
AT huojianxin mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines
AT huangyuhan mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines
AT teoshuanyong mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines
AT duankaibo mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines
AT liyanfeng mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines
AT tohlimkai mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines
AT lamkongpeng mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines
AT xushengli mrnaboostervaccinationenhancesantibodyresponsesagainstsarscov2omicronvariantinindividualsprimedwithmrnaorinactivatedvirusvaccines